NEW HAVEN, Conn., Sept. 9 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today the formation of its Clinical Advisory Board. The Board, comprised of six infectious disease specialists, will provide oversight and counsel on matters related to the Company's clinical development programs.
Dr. Robert C. Moellering, Jr., M.D., will serve as Chairman of the Clinical Advisory Board. From 1999 to 2005, Dr. Moellering was the Herrman L. Blumgart Professor of Medicine at Harvard Medical School and Chairman of the Department of Medicine at Beth Israel Deaconess Medical Center, Boston. He now holds the Shields Warren-Mallinckrodt Chair of Medical Research at Harvard Medical School, and was the founder and served as the CEO of the Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center until 2004.
Other individuals named to the Advisory Board include:
-- Helen W. Boucher, M.D., Assistant Professor of Medicine, Tufts University School of Medicine, Director of the Infectious Diseases Fellowship Program, and Staff Physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, Boston;
-- Henry F. Chambers, M.D., Chief Professor of Medicine in the Division of Infectious Diseases at San Francisco General Hospital, and the Director of the University of California, San Francisco Infectious Diseases Fellowship Training Program;
-- Barbara E. Murray, M.D., Director of the Division of Infectious Diseases at the University of Texas-Houston Medical School, and Co-Director of the UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens;
-- Leon G. Smith, M.D., Professor of Medicine and Preventive Medicine /
Community Health at the University of Medicine and Dentistry of New Jersey,
Chair of the Residency P
|SOURCE Rib-X Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved